|
Prolyl hydroxylase inhibitor FG-2216 results in increased EPO production by ESRD kidneys and liver. |
 |
 |
|
Ivanhoe: Treatment with FG-2216 considerably increased EPO production in dialysis patients, in addition to healthy people with normal kidneys. The utmost increase in EPO production occurred in dialysis patients whose kidneys were still present, but no longer functioning. FG-2216 additionally stimulated EPO production in dialysis patients with no kidneys. These are individuals whose kidneys had been removed at surgery for cancer or other diseases. The significant increase in EPO production in patients devoid of kidneys was approximately as high as in people with normally functioning kidneys. In patients with no kidneys, FG-2216 in fact stimulated production of EPO by the liver.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
